[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hypercoagulability\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hypercoagulability":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100527871","phase-3-prolonged-hypercoagulability-following-major-liver-resection-for-malignancy-100527871",false,"NCT06153394","Prolonged Hypercoagulability Following Major Liver Resection for Malignancy","PRIORITY","Inclusion Criteria:\n\n1. Adults aged 18 years or older at the time of enrollment.\n2. Requiring major liver resection (\\>2 liver sections) for any oncologic indication.\n3. Requiring postoperative thromboprophylaxis will be included.\n4. Willing and able to perform subcutaneous injections according to the study protocol, or receive injections form a caregiver delegated by the participant.\n\nExclusion Criteria:\n\n1. Anyone below 18 years of age.\n2. Patients on current anticoagulant and\u002For antiplatelet therapy\n3. Patients with a history of thrombotic events\n4. Patients with a coagulation disorder.\n5. Patients with recognized thrombophilia.\n6. Patients who cannot understand\u002Fspeak or read in English.","ALL","18 Years",{"count":19,"type":20},50,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","This clinical trial will investigate the ability of thromboelastrogrpahy (TEG®) to detect hypercoagulability after liver surgery and will examine the effect of extended thromboprophylaxis (medical treatment to prevent the development of blood clots inside blood vessels) in patients undergoing liver surgery for cancer treatment.\n\nThe liver plays a key role in regulating the process of blood clotting. As a result, blood clots are a major cause of complications and death following liver surgery. This is especially true in cancer patients who are at a higher risk of developing blood clots. Current methods for preventing clotting complications after liver surgery include conventional coagulation blood tests (CCTs) and anticoagulant drugs, such as low molecular weight heparins (LMWHs). Current LMWH treatment is prescribed for one month after surgery, but studies show that the risk of developing blood clots can last up to 3 months. Studies also show that CCTs may not be as effective in detecting clotting issues as more comprehensive testing systems, such as TEG. This study will randomize 50 participants to receive 90 days of thromboprophylaxis (using the LMWH Redesca) or the standard of care 30 days (using the LMWH Fragmin) after liver surgery. The medication will be given by injection, similar to a regular vaccine or an insulin injection. Participants will inject the medication every day, for 30 or 90 days, after surgery. Participants will also have their blood tested for clotting issues via TEG testing before surgery and on post-operative days 1,3,5,30 and 90. After surgery, participants will be monitored by their surgeon for clotting complications and 3 year disease-free survival.",[26,27,28,29],"Hepatic Disease","Surgery-Complications","Hypercoagulability","Thrombosis","NOT_YET_RECRUITING","2024-04-22",{"date":33,"type":34},"2024-04-23","ACTUAL",{"date":36,"type":20},"2024-06-01",{"date":38,"type":20},"2028-02-01",{"name":40,"class":41},"Western University, Canada","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":42},"100480811","phase-2-viscoelastic-testing-guided-tissue-plasminogen-activator-treatment-in-acute-respiratory-failure-100480811","NCT05540834","Viscoelastic Testing Guided Tissue Plasminogen Activator Treatment in Acute Respiratory Failure","A Phase 2 Safety, Dose-finding and Efficacy Study Evaluating Viscoelastic Testing (VET) Guided Tissue Plasminogen Activator (tPA) Treatment in Critically-ill Pro-thrombotic Acute Respiratory Failure","VETtiPAT-ARF","Inclusion Criteria:\n\n1. Acute respiratory failure of primary pulmonary infectious or extrapulmonary infectious aetiology with severity graded by the arterial oxygen partial pressure to inspired fraction of oxygen ratio (P\u002FF) as per the Berlin definition: acute onset of hypoxemia with an arterial partial pressure of oxygen (PaO2) to inspired fraction of oxygen (FiO2) ratio of less than or equal to 300 mmHg with positive end expiratory pressure (PEEP) of 5 cm of water (H2O) or greater\n2. Requiring admission to Intensive Care\n3. Aged 18 - 75 years of age\n4. Procoagulant profile on ClotPro (TradeMark) fibrinogen (FIB)-test +\u002F- extrinsic coagulation pathway (EX)-test - above normal range for amplitude at 10 minutes (A10) and\u002For maximal clot firmness (MCF) at 30 minutes run time\n5. Lysis Time on ClotPro tissue plasminogen activator (TPA)-test ClotPro equal to or greater than 365 seconds\n\nExclusion Criteria:\n\n1. Platelet count \\\u003C150 x 109\u002FL or a reduction in platelet count of 50% or more in the last 24 hours\n2. Body weight \\\u003C 60 kg\n3. Structural intracranial disease e.g. arterio-venous malformation or aneurysm\n4. Previous intracranial haemorrhage\n5. Ischaemic stroke within 3 months\n6. Traumatic cardiopulmonary resuscitation\n7. Hypoxaemia from traumatic lung injury\n8. Active or recent bleeding\n9. Recent surgery, trauma or invasive procedure\n10. Systolic blood pressure (BP) \\> 180 mm Hg\n11. Diastolic BP \\> 100 mm Hg\n12. Pericarditis or pericardial fluid\n13. Diabetic retinopathy\n14. Currently menstruating\n15. Pregnancy - (beta-human chorionic gonadotropin (HCG) to be performed if of child-bearing age)\n16. Liver failure (known severe liver disease or an alanine aminotransferase or an aspartate aminotransferase level that is 5 times the upper limit of normal)\n17. Kidney failure (estimated Glomerular Filtration Rate (eGFR =\\\u003C30 mL\u002Fhr or receiving renal replacement therapy)\n18. Use of therapeutic anticoagulation or platelet antagonists\n19. Not for active treatment\n20. Unlikely to survive until the day after tomorrow","75 Years",{"count":53,"type":20},70,[55],"PHASE2","Patients with coronavirus disease (COVID) and non-COVID acute respiratory failure (ARF) may be at an increased risk of thrombosis due to increased clot formation and decreased clot lysis. This two stage study aims to utilise bedside coagulation technology to detect patients at increased risk and guide tPA treatment to maximise efficacy and safety through a personalised approach.",[58,28,59],"Acute Respiratory Failure","Fibrinolysis Shutdown","RECRUITING","2024-04-15",{"date":63,"type":34},"2024-04-17",{"date":65,"type":34},"2022-05-18",{"date":67,"type":20},"2026-12-01",{"name":69,"class":41},"South West Sydney Local Health District"]